Follow‐up after systemic adverse reactions of immunotherapy
Authors:
Abstract
Out of 280 immunotherapy (IT)‐treated patients in our allergy clinic, 37 (13%) developed systemic adverse reactions. Parietaria judaica (Pj) extract, a highly allergenic pollen in northern Israel, was part of the IT regimen in 46% of treated patients who developed systemic adverse reactions. Twenty‐six (70%) of systemic adverse reactions occurred during the buildup phase, whereas 11 (30%) occurred in the maintenance phase of treatment. Mild systemic reactions developed in 15/37 (40%), moderate in 20/37 (54%), and severe in 2/37 (5%) of patients. In 22/37 (59% of our IT‐treated patients, adverse reactions developed within 30 min after injection. Among these were the two patients with severe systemic reactions. In 19%, moderate adverse reactions appeared at 30–60 min; in 22%, mild to moderate reactions appeared after 1–2 h. Our study concludes that severe systemic reactions to IT usually appear within 30 min after injection. In Israel, IT with highly allergenic pollens such as Pj frequently causes systemic reactions, even during the maintenance phase of treatment. In such cases, the reduction of IT dosage should be more than 50% during the pollen season, and a waiting period of 1 h should also be considered.Keywords
This publication has 3 references indexed in Scilit:
- Guidelines to minimize the risk from systemic reactions caused by immunotherapy with allergenic extractsJournal of Allergy and Clinical Immunology, 1994
- The waiting period after allergen skin testing and immunotherapyJournal of Allergy and Clinical Immunology, 1990
- Clinical and immunologic aspects of allergen-specific immunotherapy in patients with seasonal allergic rhinitis and/or allergic asthmaJournal of Allergy and Clinical Immunology, 1983